As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse PALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as...

Protega Pharmaceuticals™ LLC Announces Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S. RoxyBond is the first and only immediate-release opioid medication with FDA-approved labeling describing abuse-deterrent properties.1 PRINCETON, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Protega...

Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200 NORTHVALE, N.J., June 9, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing...